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Abstract
Introduction: Every new HIV infection is preventable and every HIV-related death is avoidable. As many jurisdictions around the
world endeavour to end HIV as an epidemic, missed HIV prevention and treatment opportunities must be regarded as public
health emergencies, and efforts to quickly fill gaps in service provision for all people living with and vulnerable to HIV infection
must be prioritized.
Discussion: We present a novel, comprehensive, primary and secondary HIV prevention continuum model for the United States
as a conceptual framework to identify key steps in reducing HIV incidence and improving health outcomes among those vulnerable
to, as well as those living with, HIV infection. We further discuss potential approaches to address gaps in data required for
programme planning, implementation and evaluation across the elements of the HIV prevention continuum.
Conclusions: Our model conceptualizes opportunities to monitor and quantify primary HIV prevention efforts and, importantly,
illustrates the interplay between an outcomes-oriented primary HIV prevention process and the HIV care continuum to move
aggressively forward in reaching ambitious reductions in HIV incidence. To optimize the utility of this outcomes-oriented
HIV prevention continuum, a key gap to be addressed includes the creation and increased coordination of data relevant to HIV
prevention across sectors.
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Introduction
The HIV care continuum has become a highly visual, accessible
and reproducible model to improve health outcomes and
minimize transmission risk among those living with the virus
[1]. Viral load suppression is viewed not only as the con-
tinuum’s central outcome to minimize individual morbidity
and mortality, but also as a key intervention for secondary
HIV prevention, given that viral suppression reduces the risk of
HIV transmission [2]. Reducing the risk of HIV acquisition
among those not already infected and vulnerable to HIV
exposure is equally essential.
An HIV prevention continuum, like the care continuum, is
potentially valuable to identify opportunities at key steps in an
HIV incidence- and health outcomes-oriented process. Such a
model affords the opportunity to: 1) define best biomedical,
behavioural and ancillary support practices, including those
that foster integration of HIV prevention with broader primary
care, wellness promotion and sexual and reproductive health
services; 2) further articulate and refine themetrics of success;
3) identify gaps in provider/intervention access and utilization;
4) inform the allocation of human and financial resources;
5) establish implementation science priorities; and 6) generate
and support advocacy for the highest impact HIV prevention
activities.
Primary HIV prevention continua and similar heuristics
have been developed by others. These include a generalized,
population-based approach [3]; an infection cascade and
prevention pathways model [4]; and pre-exposure prophy-
laxis (PrEP) and other intervention-specific cascades [57].
Proposed models are not without limitations, however.
Most fundamentally, unlike engagement in specialized care
and antiretroviral therapy after an HIV diagnosis, initiation of
a particular intervention following an HIV-negative diagnosis
is neither routine nor straightforward. HIV prevention needs
and options are not universal or static because of individual
and intrapopulation variability and temporal fluctuations
in risk. Additionally, few proposed models address congruity
with the HIV care continuum. A heuristic device illustrating
the importance of both primary and secondary HIV preven-
tion may prove useful in further influencing HIV incidence.
Recognizing inherent challenges, we present a novel con-
tinuummodel for the United States as a conceptual framework
for addressing individualized primary HIV prevention needs
to achieve population-level reductions in HIV acquisition risk
and to illustrate the critical link between a comprehensive
primary prevention process and the care continuum to further
improve health outcomes and minimize transmission risk
among those who are infected with HIV. To bolster stakeholder
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interest in this model, particularly among U.S. public health
departments, we discuss potential approaches to address gaps
in data required for programme planning, implementation,
and evaluation across the elements of the primary HIV
prevention continuum.
Discussion
Our model, shown in Figure 1, configures the primary HIV
prevention continuum as a cycle, recognizing that the primary
goal of remaining HIV negative, confirmed by repeat testing, is
not a static process but rather a dynamic one, dependent on
population, network and individual fluctuations in biomedical
and supportive care needs over time. For example, not all HIV-
negative gay, bisexual and other men who have sex with men
will necessarily benefit from the HIV protection afforded by
PrEP, including some men in sexually exclusive relationships
and men who use condoms consistently and effectively.
Even among those for whom PrEP is indicated and desired,
utilization may be limited due to transient periods of risk.
A unique feature of the proposed model is a depiction
of the link between the primary HIV prevention continuum
and the HIV care continuum and the critical interplay of both
in maximizing health outcomes and minimizing ongoing
spread of the virus. For example, an HIV-negative individual
who seroconverts while engaged in a prevention programme
featuring regular HIV testing may quickly be linked to and
engaged in HIV care and, thereby, benefit from early anti-
retroviral therapy, including reduction in further onward HIV
transmission.
HIV testing and retesting
HIV testing is the entry point in the HIV prevention cycle,
as it generally provides a critical point of contact with the
healthcare and service delivery systems for individuals who
are HIV negative but are vulnerable to the infection, as well as
being a gateway to treatment for people diagnosed with HIV
infection. The cycle is repeated for as long as an individual
remains at risk for HIV acquisition. In effect, 100% of people
at risk for HIV infection who test seronegative at the
beginning and end of one cycle should re-enter the cycle and
be retested at least annually [810], coupled with regular HIV
prevention risk and needs assessments to determine linkage
and intervention needs.
Risk and needs assessment
As part of a comprehensive prevention strategy, following
a negative HIV test, people vulnerable to HIV infection should
receive risk and needs assessments. These can best ensure
linkage to medical and other service providers capable of
providing or coordinating evidence-based interventions and
social services appropriate for that individual. The cyclical
framework of our model, with HIV retesting as a central indi-
cator, allows for repeated risk and needs assessments to
meet an individual’s changing HIV prevention requirements.
For those testing for HIV in acute care (e.g. emergency
departments) or non-healthcare settings (e.g. community-
based organizations (CBOs)), minimum assessments may
include knowledge of and eligibility for a range of risk-
reduction strategies, including PrEP, in accordance with U.S.
Centers for Disease Control and Prevention (CDC) recommen-
dations, and healthcare provider and insurance status
navigation needs [11]. For vulnerable individuals testing for
HIV in healthcare settings, or having been referred for HIV
prevention services by an acute care or non-healthcare testing
site, possible assessments include the following: screenings
for sexually transmitted infections, mental health disorders,
substance abuse, intimate partner violence and trauma;
adequacy of health insurance to cover necessary prevention
services; and other primary or specialty care needs [12,13].
The development of simple risk and needs assessment
instruments, including online self-assessment and navigation
tools, to help maximize linkage to and engagement in HIV
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Figure 1. Comprehensive HIV prevention processes. Conceptual framework illustrating the interplay between processes to halt both the
acquisition and transmission of HIV. The primary HIV prevention cycle, left, begins with HIV testing. Risk and needs assessments, linkage to
services, engagement in risk-reduction prevention interventions and HIV testing are repeated for as long as an individual remains at risk for
HIV acquisition.
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prevention services while minimizing the added burden to
providers and systems should be an implementation priority.
Linkage to prevention services
For individuals tested for HIV and having undergone compre-
hensive risk and needs assessments in primary care settings,
linkage may include referrals to specialized medical, mental
health and substance abuse services and CBO-provided
psychosocial and ancillary services (e.g. housing, employment,
nutritional and social support) [12,13]. For individuals tested
for HIV and having undergone basic risk assessments in acute
and non-healthcare settings, linkage to culturally sensitive
medical and other service providers with knowledge and
experience providing or coordinating various primary HIV
prevention interventions is essential [11]. These may include
providers in primary care settings; reproductive, sexual,
transgender or other community health programmes (includ-
ing PrEP clinics); and intervention programmes at CBOs. In all
cases, assistance with health insurance and other benefits,
including linkage to health insurance navigators, case manage-
ment and intervention-specific programmes (e.g. PrEP
medication and co-pay assistance programmes), must be
prioritized to ensure adequate coverage for medical care and
other services identified as necessary during risk and needs
assessments.
Engagement, retention and adherence
The final element in the primary prevention cycle addresses
uptake of, engagement in and adherence to optimal, high
quality HIV prevention and risk-reduction interventions.
These include PrEP; post-exposure prophylaxis (PEP); syringe
exchange programmes (SEPs) and substance abuse treat-
ment; mental health services; housing assistance; sexual
health services; and behavioural change interventions. To
help optimize engagement in HIV prevention programmes
and related systems of care, the use of culturally competent
case managers, patient navigators and/or other client-
centred services should be considered [1418].
Obtaining essential data
In contrast to the relatively straightforward data elements
used to assess outcomes along the HIV care continuum,
the metrics required to populate a primary HIV prevention
continuum involving different systems of service delivery,
interventions and outcome measures are incredibly complex
and often without adequate or complete population-based
data sources. Here we discuss two potential approaches to
address the gaps in data required for programmatic planning,
implementation and evaluation across the elements of the
prevention cycle.
Primary HIV prevention continuum metrics
One strategy involves coordinating existing HIV prevention-
related data. For example, the U.S. CDC, utilizing data from
the National Health and Nutrition Examination Survey, the
National Survey on Drug Use and Health and the National
Survey of Family Growth, has estimated the number of U.S.
adults with indications for PrEP based on behavioural risk
factors for HIV and the 2014 U.S. Public Health Service’s PrEP
clinical practice guideline to be 1,232,000 (95% confidence
interval: 661,000 to 1,803,000) [19,20]. This effort to organize
and analyze data across national surveys produced a valuable
estimate of the number of US adults at elevated HIV risk,
which could be used immediately as a lower-bound threshold
for the prevention cycle’s primary denominator, as well as to
evaluate PrEP coverage and advocate for scale-up.
A similar large-scale effort to identify and validate data
sources for mid-cycle elements of the HIV prevention con-
tinuum, such as rates of health insurance coverage, linkage
to service providers and utilization of evidence-based inter-
ventions, has not yet been undertaken. One potential data
source for this work might be the National HIV Prevention
Program Monitoring and Evaluation (NHM&E) system, which
collects current and prior HIV testing data, referrals to specific
HIV prevention activities and ‘‘intervention completion’’
each time a client enrols in or completes an intervention after
HIV testing at a CDC directly funded CBO [21]. Available
publications, presentations and reports from NHM&E data
focus primarily on HIV testing results [2224]. Collating
and publishing data on referrals and completion of HIV
prevention services, as well as indication for HIV testing,
would be an important contribution  albeit a labour-intensive
one  to informing HIV prevention service coverage and
building local or national HIV prevention continua. Other
potential data sources to inform elements of the HIV preven-
tion cycle are listed in Table 1.
Identifying ‘‘missed opportunities’’ and primary HIV
prevention continuum gaps
A second approach includes leveraging extant, robust HIV
surveillance data among individuals who tested positive for
the virus. Since the early days of the U.S. epidemic, such data
pertaining to transmission risk among individuals testing
positive for HIV have been used to inform HIV prevention
planning and funding.
Each new infection continues to represent a missed
opportunity for primary HIV prevention. In the setting of
expanded prevention options available to those vulnerable to
HIV infection, there is a need for renewed and strategic use
of HIV surveillance data on new diagnoses to systematically
understand prevention gaps and missed prevention oppor-
tunities, with rapid translation to ‘‘reverse engineer’’ primary
HIV prevention continuum element priorities. Other areas of
public health, including efforts to prevent maternal mortality,
have employed similar approaches and have benefited from
studying ‘‘near misses’’ in order to inform population-level
best practices and implementation strategies [2527].
Current CDC data systems allow for the collection of
information to make some inferences about an individual’s
attributable risk factor(s) for HIV acquisition and to track
linkages to appropriate services after receiving a positive
diagnosis. However, not enough surveillance data are gath-
ered following diagnosis to learn about missed HIV prevention
opportunities inherent in every new HIV infection. Treating
each new infection as an sentinel health event is necessary to
understand exactly where gaps in the primary HIV prevention
continuum are occurring, especially as PrEP and PEP imple-
mentation is ramping up in many jurisdictions. Examples of
probable gaps include the following: lack of knowledge
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regarding the symptoms of, and high transmission risk
during, acute HIV infection; lack of awareness or availability
of PrEP, PEP, SEP or other interventions; poor retention in or
adherence to prevention services; and structural barriers to
affordable health insurance, adequate medical care, safe
housing or other supportive services. A fundamental assump-
tion in the reverse engineering approach is that people
vulnerable to HIV infection will have similar characteristics
and risk factors to those who were recently diagnosed,
such that extrapolation of data between populations is valid.
Local programmes targeted at increasing early or immediate
treatment following HIV testing, such as the University of
California, San Francisco’s RAPID programme [28], are well
poised to collect data on recently diagnosed individuals and
inform data for local HIV prevention gaps.
Conclusions
Our proposed model provides a standardized roadmap for
moving aggressively forward in reaching national HIV inci-
dence and care targets by: 1) conceptualizing primary HIV
prevention as a repeating, comprehensive and outcomes-
oriented process that is applicable to vulnerable populations
comprised of individuals with fluctuating risks and interven-
tion needs; and 2) illustrating the value of HIV retesting as
both a metric to continuously gauge the effectiveness of the
primary HIV prevention cycle and an opportunity to stream-
line successful linkage, engagement and viral load suppression
through the HIV care continuum. A limitation of our model
is the absence of the complete data required to test the
proposed primary HIV prevention continuum steps, which
will be necessary indicators of success. An obstacle to model
validation is the lack of a robust and coordinated HIV pre-
vention monitoring system, which is sorely needed to help
guide the implementation of key modalities of HIV preven-
tion, such as PrEP and PEP. Our hope is that, in suggesting
a way forward, we can catalyze an effort to address these
limitations, which have stymied the promulgation of a
meaningful primary HIV prevention continuum to date.
Given the current state of data collection infrastructure in
the United States, efforts to vitalize HIV prevention will need
to focus on increasing coordination between existing systems,
including those not specifically focused on HIV, to prioritize
the reporting of data for people vulnerable to HIV infection.
The need for these data, however, must be weighed against
efforts to decrease federal data collection and reporting
burdens among health departments and CBOs as well as the
need for increased resources required to more fully support
these surveillance activities. Creating new primary preven-
tion-focused variables in existing data collection tools, as
well as conducting more analyses of current variables, will
inform regional, state and national public health evaluation
of prevention service coverage, identify gaps and facilitate
Table 1. Potential elements, metrics and data sources for the primary HIV prevention cycle
Step HIV testing and retesting Risk and needs assessment
Linkage to prevention
services
Engagement, retention
and adherence
Elements and
metrics
Testing through: community
health centres; physician
offices; hospital-based
inpatient and ambulatory care
clinics; emergency
departments;
CBO/ASO; home/self-testing;
harm reduction and substance
use programmes; mobile/
venue-based units
STI screening; pregnancy and
family planning; mental health
and substance abuse; trauma
and violence; insurance
coverage; primary care
engagement; housing and
employment status; and
sexual health screenings
Documented linkage to:
health insurance, including
ACA/health insurance
navigation; primary care
provider or community-based
PrEP or PEP providers; syringe
exchange and other harm
reduction programmes; and/
or DIS/public health
departments
Engagement (number/type
of visits); client-provider
relationship; intervention
adherence (e.g. uptake and
continued utilization of PrEP
and PEP)
Data sources NHM&E; health departments;
community clinics; labs (public
and private); ACA plans; CMS
and state Medicaid databases;
Veterans Administration health
centres; prisons and jails;
Bureau of Primary Health Care/
HRSA; ob-gyn; emergency
rooms
ICD 9 and 10; CBO
programmatic and client data;
Healthy People 2020
NHM&E; additional data
sources needed
NHM&E, BRFSS, YRBS, NHBS,
NSFG, PRAMS, CMS, and
MMP hospital discharge data;
data brokers; Medicaid
registries; and CBO
programme data, including
housing and supportive
services
ACA, the Patient Protection and Affordable Care Act; ASO, AIDS service organization; BRFSS, Behavioral Risk Factor Surveillance System; CBO,
community-based organization; CMS, the Centers for Medicare and Medicaid Services; DIS, disease intervention specialists; HRSA, Health
Resources and Services Administration; MMP, Medical Monitoring Project; NHBS, National HIV Behavioral Surveillance; NHM&E, National HIV
Prevention Monitoring and Evaluation; NSFG, National Survey of Family Growth; PEP, post-exposure prophylaxis; PRAMS, Pregnancy Risk
Assessment Monitoring System; PrEP, pre-exposure prophylaxis; STI, sexually transmitted infection; YRBS, Youth Risk Behavior Surveillance
System.
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advocacy for scale-up of highly effective prevention services
in the United States.
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